Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too?
| العنوان: | Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: Can we have our cake and eat it too? |
|---|---|
| المؤلفون: | Anthony T. Vella, Adam J. Adler, Joseph M. Ryan, Jeffrey S. Wasser |
| المصدر: | Expert Opinion on Biological Therapy. 16:655-674 |
| بيانات النشر: | Informa Healthcare, 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | 0301 basic medicine, Cell cycle checkpoint, Drug-Related Side Effects and Adverse Reactions, medicine.drug_class, medicine.medical_treatment, Clinical Biochemistry, Fc receptor, Antineoplastic Agents, Monoclonal antibody, Article, Immunomodulation, 03 medical and health sciences, Costimulatory and Inhibitory T-Cell Receptors, Neoplasms, Drug Discovery, medicine, Animals, Humans, Pharmacology, Tumor microenvironment, biology, Antibodies, Monoclonal, Cancer, Cell Cycle Checkpoints, Immunotherapy, medicine.disease, 030104 developmental biology, Monoclonal, Immunology, biology.protein, Antibody |
| الوصف: | Monoclonal antibodies (mAbs) targeting checkpoint inhibitors have demonstrated clinical benefit in treating patients with cancer and have paved the way for additional immune-modulating mAbs such as those targeting costimulatory receptors. The full clinical utility of these agents, however, is hampered by immune-related adverse events (irAEs) that can occur during therapy.We first provide a general overview of tumor immunity, followed by a review of the two major classes of immunomodulatory mAbs being developed as cancer therapeutics: checkpoint inhibitors and costimulatory receptor agonists. We then discuss therapy-associated adverse events. Finally, we describe in detail the mechanisms driving their therapeutic activity, with an emphasis on interactions between antibody fragment crystallizable (Fc) domains and Fc receptors (FcR).Given that Fc-FcR interactions appear critical in facilitating the ability of immunomodulatory mAbs to elicit both therapeutically useful as well as adverse effects, the engineering of mAbs that can effectively engage their targets while limiting interaction with FcRs might represent a promising future avenue for developing the next generation of immune-enhancing tumoricidal agents with increased safety and retention of efficacy. |
| تدمد: | 1744-7682 1471-2598 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b8d2a51bf5b527c1f4ae461c130cd5c6Test https://doi.org/10.1517/14712598.2016.1152256Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b8d2a51bf5b527c1f4ae461c130cd5c6 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447682 14712598 |
|---|